Literature DB >> 11408365

Bexarotene metabolism in rat, dog, and human, synthesis of oxidative metabolites, and in vitro activity at retinoid receptors.

S R Howell1, M A Shirley, T A Grese, D A Neel, K E Wells, E H Ulm.   

Abstract

The metabolism of bexarotene, a rexinoid recently approved in the United States for treatment of cutaneous T-cell lymphoma, was studied using liver slices from untreated rats and dogs, liver microsomes from untreated and pretreated rats, and pooled human liver microsomes. Metabolite profiles were examined in bile and plasma from rats and dogs, and plasma from humans treated with bexarotene. Four metabolites, racemic 6-hydroxy-bexarotene, racemic 7-hydroxy-bexarotene, 6-oxo-bexarotene, and 7-oxo-bexarotene, were synthesized and their binding to, and transactivation of retinoid receptors were examined. Qualitatively similar metabolite profiles were observed in the microsomal and liver slice extracts; the predominant metabolites were 6-hydroxy-bexarotene and glucuronides of parent or hydroxylated metabolites. Pretreatment of rats with bexarotene induced hepatic microsomal bexarotene metabolism. The hydroxy and oxo metabolites were observed in plasma of rats, dogs, and humans treated with bexarotene and 6-hydroxy-bexarotene was a major circulating metabolite. The oxidative metabolites were more abundant relative to parent in plasma from humans than from rat or dog. The predominant biliary metabolites in rat and dog were bexarotene acyl glucuronide and a glucuronide of oxidized bexarotene, respectively. Since bexarotene elimination is primarily biliary in these species, these metabolites represent the main bexarotene metabolites in rats and dogs. The binding of synthetic metabolites to retinoid receptors was much reduced relative to parent compound. The metabolites exhibited minimal activity in transactivating retinoic acid receptors and had reduced activity at retinoid X receptors relative to bexarotene. Thus, while there is substantial systemic exposure to the oxidative metabolites of bexarotene, they are unlikely to elicit significant retinoid receptor activation following bexarotene administration.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11408365

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  8 in total

1.  Bexarotene reduces network excitability in models of Alzheimer's disease and epilepsy.

Authors:  Valerie Bomben; Jerrah Holth; John Reed; Paige Cramer; Gary Landreth; Jeffrey Noebels
Journal:  Neurobiol Aging       Date:  2014-04-02       Impact factor: 4.673

2.  Chemopreventive effects of RXR-selective rexinoid bexarotene on intestinal neoplasia of Apc(Min/+) mice.

Authors:  Naveena B Janakiram; Altaf Mohammed; Li Qian; Chang-In Choi; Vernon E Steele; Chinthalapally V Rao
Journal:  Neoplasia       Date:  2012-02       Impact factor: 5.715

3.  Response to comments on "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models".

Authors:  Gary E Landreth; Paige E Cramer; Mitchell M Lakner; John R Cirrito; Daniel W Wesson; Kurt R Brunden; Donald A Wilson
Journal:  Science       Date:  2013-05-24       Impact factor: 47.728

4.  Amyloid-β pathology and APOE genotype modulate retinoid X receptor agonist activity in vivo.

Authors:  Leon M Tai; Kevin P Koster; Jia Luo; Sue H Lee; Yue-Ting Wang; Nicole C Collins; Manel Ben Aissa; Gregory R J Thatcher; Mary Jo LaDu
Journal:  J Biol Chem       Date:  2014-09-12       Impact factor: 5.157

5.  Synthesis of [(11)C]Bexarotene by Cu-Mediated [(11)C]Carbon Dioxide Fixation and Preliminary PET Imaging.

Authors:  Benjamin H Rotstein; Jacob M Hooker; Jiyeon Woo; Thomas Lee Collier; Thomas J Brady; Steven H Liang; Neil Vasdev
Journal:  ACS Med Chem Lett       Date:  2014-02-27       Impact factor: 4.345

6.  Analysis of differential secondary effects of novel rexinoids: select rexinoid X receptor ligands demonstrate differentiated side effect profiles.

Authors:  Pamela A Marshall; Peter W Jurutka; Carl E Wagner; Arjan van der Vaart; Ichiro Kaneko; Pedro I Chavez; Ning Ma; Jaskaran S Bhogal; Pritika Shahani; Johnathon C Swierski; Mairi MacNeill
Journal:  Pharmacol Res Perspect       Date:  2015-03-16

7.  A randomized controlled study to evaluate the effect of bexarotene on amyloid-β and apolipoprotein E metabolism in healthy subjects.

Authors:  Kaushik Ghosal; Michael Haag; Philip B Verghese; Tim West; Tim Veenstra; Joel B Braunstein; Randall J Bateman; David M Holtzman; Gary E Landreth
Journal:  Alzheimers Dement (N Y)       Date:  2016-06-17

8.  Induced differentiation of acute myeloid leukemia cells by activation of retinoid X and liver X receptors.

Authors:  P V Sanchez; S T Glantz; S Scotland; M T Kasner; M Carroll
Journal:  Leukemia       Date:  2013-07-04       Impact factor: 11.528

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.